Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

76.93 USD +1.42 (+1.88%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 14, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 933,064
Open 76.01
Bid (Size) 74.51 (3)
Ask (Size) 79.12 (1)
Prev. Close 75.51
Today's Range 75.59 - 77.52
52wk Range 71.35 - 131.94
Shares Outstanding 182,742,573
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
BioMarin Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting
Research Findings are Part of the Largest and Longest Development Program for any Gene Therapy in Hemophilia A and Advance the Scientific Understanding of AAV5 Gene Therapy 
From PR Newswire
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
- 7th Annual Truist Securities Life Sciences Summit on May 4 at 1:50pm ET 
From PR Newswire

Performance

YTD
-10.86%
-10.86%
1 Month
-1.66%
-1.66%
3 Month
-11.62%
-11.62%
6 Month
-0.76%
-0.76%
1 Year
-16.19%
-16.19%

More News

Read More
BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates
From PR Newswire
Allen Institute and BioMarin Team Up To Develop Gene Therapies For Rare Brain Diseases
From PR Newswire
BioMarin Announces New and Updated Data at 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting Demonstrating Commitment to Understanding Achondroplasia and P
From PR Newswire
BioMarin to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, April 29 at 4:30pm ET
From PR Newswire
BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society's Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide
From PR Newswire
Analysts Forecast 10% Upside For The Holdings of VUG
Tags ETFs
From ETF Channel
Biomarin Pharmaceutical: Q1 Earnings Insights
Tags BMRN BZI/Recaps Benzinga
From Benzinga
Why Sarepta's Q1 Results Won't Spark a Rebound for the Beaten-Down Biotech
Tags Market News SRPT RHHBY
From Motley Fool
Preview: Biomarin Pharmaceutical's Earnings
Tags BZI/EP BMRN Market News
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback